Literature DB >> 11501174

Gender difference in letrozole pharmacokinetics in rats.

X D Liu1, L Xie, Y Zhong, C X Li.   

Abstract

AIM: To study gender difference in letrozole (Letr) pharmacokinetics in rats.
METHODS: Letr concentrations in plasma and tissues were determined after ig administration of Letr 2 mg/kg. Recoveries of Letr in urine and feces were also analyzed.
RESULTS: Marked gender differences were found 6 h after ig Letr 2 mg/kg, the plasma concentrations of Letr in male rats were significantly (P < 0.01) lower than those in female rats. For example, at 24, 36, 48, and 72 h after administration, plasma concentrations in female rats were about 3.3, 5.6, 10.5, and 7.4-fold of that of male rats, respectively. AUC value of Letr in male was only about one-third of that in female rats. Estimated terminal phase half-lives (T1/2) were 10.5 and 40.4 h, respectively. In female rats, cumulative excreted fractions of Letr in urine and feces were 5.8% +/- 1.4% and 6.6% +/- 1.1% within 120 h after administration, respectively, but in male rats, the excreted fractions of Letr in urine and feces were only 1.30% +/- 0.59% and 0.87% +/- 0.31%. Letr concentrations in female rat tissues were significantly (P < 0.01) higher than those in male rat tissues 24 h after administration.
CONCLUSION: There are marked gender differences in Letr pharmacokinetics in rats.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11501174

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  4 in total

1.  Gender difference in ranolazine pharmacokinetics in rats.

Authors:  X D Liu; L Xie; Y Liang; L Li; T Lu
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2003 Apr-Jun       Impact factor: 2.441

2.  Gender differences in limonin pharmacokinetics in rats.

Authors:  Y Liang; L Xie; X D Liu; Y Z Hu; T Lu; G J Wang
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2005 Oct-Dec       Impact factor: 2.441

3.  Inhibition of drug metabolizing cytochrome P450s by the aromatase inhibitor drug letrozole and its major oxidative metabolite 4,4'-methanol-bisbenzonitrile in vitro.

Authors:  Seongwook Jeong; Margaret M Woo; David A Flockhart; Zeruesenay Desta
Journal:  Cancer Chemother Pharmacol       Date:  2009-02-07       Impact factor: 3.333

4.  Gender-based differences in brain and plasma pharmacokinetics of letrozole in sprague-dawley rats: Application of physiologically-based pharmacokinetic modeling to gain quantitative insights.

Authors:  Priyanka Arora; Gary Gudelsky; Pankaj B Desai
Journal:  PLoS One       Date:  2021-04-02       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.